Program Schedule

Saturday, November 10
7:00 am – 6:00 pm Registration Open
8:00 am – 8:10 am Announcements
Jon M. Wigginton, MD
Center for Cancer Research
National Cancer Institute
8:10 am – 9:05 am Keynote Address
A Genomic Approach to the Discovery of Therapeutic Proteins and Antibody Drugs
William Haseltine, PhD
Human Genome Sciences, Inc.
9:05 am – 11:30 am Pharmacogenomics/Discovery
Benjamin G. Cocks, PhD
Incyte Genomics, Inc.

Robert Zimmerman, SD
Bayer Pharmaceutical Division

9:05 am – 9:30 am Pharmacogenomic Applied to
Drug Development

Joseph Rininger, PhD
CuraGen Corporation
9:30 am – 9:55 am Directed Molecular Evolution of Vaccines and Immunotherapeutics
Juha Punonnen, MD, PhD
Maxygen, Inc.
9:55 am – 10:15 am Break
10:15 am – 10:40 am Approaches for Identifying and Accelerating the Prioritization of All the Potential Targets and Therapeutic Proteins in the Genome
Benjamin G. Cocks, PhD
Incyte Genomics, Inc.
10:40 am – 11:05 am Classification and Diagnostic Prediction
of Cancers using Gene Expression Profiling and Artificial Neural Networks

Javed Khan, MD
Center for Cancer Research
National Cancer Institute
11:05 am – 11:30 am Clinical Proteomics: Toward Personalized Molecular Medicine
Lance Liotta, MD, PhD
Center for Cancer Research
National Cancer Institute
11:30 am – 1:00 pm SBT Member Lunch/Business Meeting (SBT Members Only)
11:30 am – 1:00 pm Box Lunch/Posters Session (authors must be present)
1:00 pm – 2:30 pm Presidential Session
Chair: Robert O. Dillman, MD
SBT President
Hoag Cancer Center
1:00 pm – 1:15 pm Ranitidine as Adjuvant Treatment in Colorectal Cancer: Influence of Blood Transfusion and Postoperative Bacterial Infections
Hans Jorgen Nielsen, MD
Hvidovre University Hospital
1:15 pm – 1:30 pm Phase I/IB trial of the Immunocytokine hu14.18-IL2 in Patients with
GD2-Positive Tumors

David King, MD
University of Wisconsin, Comprehensive Cancer Center
1:30 pm – 1:45 pm Prophylactic Antitumor Efficacy of a Combination Therapy With a Xenogeneic Cell Line Producing Flt3-Ligand (FL), Tumor Cell Lysate, and Interleukin-2 in Mice With Syngeneic Colon Cancer
Eugene Kim, MD
State University of New York at Brooklyn School of Medicine
1:45 pm – 2:00 pm Inhibition of Tumor Progression and Neoangiogenesis Using Cyclic RGD- Peptides in a Chemically Induced Colon Carcinoma in Rats
Joerg Haier, MD, PhD
University Hospital Muenster, Molecular Biology Lab
2:00 pm – 2:15 pm Intratumoral Expansion of Tumor-Specific B Cells in Invasive Ductal Carcinoma of the Breast
Julia A. Coronella, PhD
University of Arizona, Arizona Cancer Center
2:15 pm – 2:30 pm Signaling Defects in CD8+CD27- CD45RO- Circulating Effector Cells in Patients with Cancer
Iris Kuss, MD
University of Pittsburgh Cancer Institute
2:30 pm – 2:50 pm Break


Concurrent Session 1
Concurrent Session 2
2:50 pm – 4:55 pm Antibody Therapy
Thomas Davis, MD
Medarex, Inc.Stephen Gillies, PhD
Lexigen Pharmaceuticals Corporation
2:50 pm – 4:50 pm Gene Therapy
Stanton Gerson, MD
Case Western Reserve University 
2:50 pm – 3:10 pm CD 22-Directed Immunotherapy of Lymphoma
John Leonard, MD
Cornell University
2:50 pm – 3:15 pm Transplantation of Stem Cells: Homing and Selection with Drug Resistance Genes
Stanton Gerson, MD
Case Western Reserve University
3:10 pm – 3:30 pm Humanized Anti–HLA-DR Monoclonal Antibody Hu1D10 (Remitogen) for the Treatment of Relapsed Non-Hodgkin’s Lymphoma: A Phase I Trial
Brian K. Link, MD
University of Iowa, Holden Comprehensive Cancer Center
3:15 pm – 3:40 pm Clinical Results of a PSA-Selective, Replication-Competent Adenovirus for the Treatment of Prostate Cancer
Theodore DeWeese, MD
Johns Hopkins Oncology Center
3:30 pm – 3:50 pm Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (anti-CTLA-4) Monoclonal Antibody (MDX-CTLA-4) in Patients with Metastatic Melanoma
Stephen Hodi, MD
Dana-Farber Cancer Institute
3:40 pm – 4:05 pm Speaker TBD
3:50 pm – 4:10 pm Early-Phase Clinical Development of the Immunocytokine EMD 273066 (huKS-IL2): Laboratory and Safety Findings in Patients with Prostate Cancer
Lothar Finke, MD
EMD Pharmaceuticals
4:05 pm – 4:30 pm Differential Impact of Local Production Interleukin-2 and Interleukin-12 on Initial Appearance and Long-term Progression of B16F10 Melanoma in Mice
Morihiro Watanabe, MD, PhD
Center for Cancer Research
National Cancer Institute
4:10 pm – 4:25 pm Synergistic Anti-tumor Responses Against Metastatic Cancer Using Antibodies to CD40 and IL2: Coordination of Dendritic Cell and T Cell Arms of the Immune Response
William J. Murphy, PhD
Center for Cancer Research
National Cancer Institute
4:30 pm – 4:45 pm A DNA Vaccine Encoding Genetic Fusions of CEA and GMCSF
Jose Lima, MD
University of Alabama at Birmingham,
Wallace Tumor Institute
4:25 pm – 4:40 pm Recurrent Murine Neuroblastomas Increase or Decrease MHC Class I Expression to Respectively Escape NK- or T Cell-Dependent Immunotherapy
Zane C. Neal, PhD
University of Wisconsin
4:45 pm – 5:00 pm Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti- Transferrin Receptor scFv
Liang Xu MD, PhD
Lombardi Cancer Center
Georgetown University
4:40 pm – 4:55 pm Combined Administration of Antibodies to Human Interleukin-8 and Epidermal Growth Factor Receptor Results in Increased Anti-metastatic Effects on Human Breast Carcinoma Xenografts
Rosalba Salcedo, PhD
Center for Cancer Research
National Cancer Institute
5:00 pm – 6:30 pm Presidential Reception/Presidential Award Announcement
Chair: Robert O. Dillman, MD
SBT President
Hoag Cancer Center